Phosphatidic Acids
- Name
- Phosphatidic Acids
- Accession Number
- DBCAT001465
- Description
Fatty acid derivatives of glycerophosphates. They are composed of glycerol bound in ester linkage with 1 mole of phosphoric acid at the terminal 3-hydroxyl group and with 2 moles of fatty acids at the other two hydroxyl groups.
- Drugs
Drug Drug Description Phosphatidyl serine A nutrient used in some supplement products. 1,2-dihexadecanoyl-sn-glycero-3-phosphoethanolamine Not Available Platelet Activating Factor Not Available Lysophosphatidylglycerol Not Available sn-glycero-3-phosphoethanolamine Not Available Cadaverine Cadaverine is a foul-smelling diamine formed by bacterial decarboxylation of lysine. Phosphatidylethanolamine Not Available L-Dilinoleoyllecithin Not Available Choline alfoscerate A natural choline that is used to manage declining cognitive function associated with neurodegenerative and vascular diseases. Lucinactant Intended for the prevention of respiratory distress syndrome (RDS) in premature infants at high risk for RDS. ETC-588 Investigated for use/treatment in atherosclerosis, coronary artery disease, and vascular diseases. Colfosceril palmitate A pulmonary surfactant used for the treatment of Respiratory Distress Syndrome (RDS) in premature infants. DL-dimyristoylphosphatidylcholine DL-dimyristoylphosphatidylcholine is not an active pharmaceutical agent and has no indication. DL-dimyristoylphosphatidylglycerol DL-dimyristoylphosphatidylglycerol is not an considered an active pharmacological ingredient in pharmaceutical preparations and so has no official indications. Mifamurtide A muramyl dipeptide derivative used to treat high grade, resectable, non-metastatic osteosarcoma after surgical resection. 1,2-Distearoyllecithin Not Annotated VB-201 VB-201 is under investigation in clinical trial NCT01001468 (Study to Assess VB-201 in Patients With Psoriasis). Lecithin Fatty substances commonly found in nutritional supplements. Iopofosine I-131 Iopofosine I-131 (NM-404 I-131) is under investigation in clinical trial NCT01495663 (Dose Escalation Study of I-131-CLR1404 in Subjects With Cancer That Does Not Respond to Treatment or Has Returned). 1,2-Dioleoyl-sn-glycero-3-phospho-L-serine Not Annotated CHF5633 CHF5633 is a fully synthetic pulmonary surfactant preparation comprising DPPC (dipalmitoylphosphatidylcholine), POPG Na (palmitoyl‐oleoyl‐phosphatidylglycerol sodium), a synthetic SP-C analogue, and a synthetic SP-B analogue. - Drugs & Drug Targets